Proviva Therapeutics

Proviva Therapeutics is a clinical-stage biotechnology company dedicated to developing a new generation of cytokine-based anti-tumor immunotherapies. To address the traditional challenge of peripheral toxicity associated with cytokines, the company has independently developed the "Crossover" cytokine prodrug technology platform, which enables specific drug activity release within the tumor microenvironment. Leveraging the "Crossover" technology platform, Proviva successfully developed PTX-912—a next-generation prodrug fusion protein targeting immune cells with interleukin-2 (IL-2).